Semaglutide provides double benefit for women with heart failure

FHS
June 24, 2024
5:08 pm

Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.

Signal: UK Biobank raises £32m in funding via public-private partnership – Pharmaceutical Technology

Rory Collins, principal investigator at the UK Biobank project in Manchester, U.K. Photo: Sean Wilton/Bloomberg via Getty Images. UK Biobank, a biomedical database of half

October 30, 2023

A new study shows how Medicaid coverage policies shape maternal health disparities

Medicaid is an essential source of maternal and postpartum care for low-income Americans, covering 42% of births in the U.S. People who give birth receive

July 18, 2023

Wojcicki projects confidence amid 23andMe stumbles

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning. It’s been a

October 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.